ALT5 Sigma Unveils Plan to Split into Two Independent Publicly Traded Companies

ALT5 Sigma Corporation, a fintech innovator specializing in advanced blockchain technologies for tokenization, trading, clearing, settlement, payment, and secure storage of digital assets, has announced a strategic initiative to separate into two distinct companies.

Following this plan’s execution, ALT5 will separate its Fintech and Biotech divisions, with ALT5 continuing as a leading fintech entity after the split. The Biotech branch will be established as Alyea Therapeutics Corporation, focusing on the development of non-addictive pain management therapies. Each entity will thus offer unique growth opportunities upon separation.

As independent companies, both organizations are anticipated to benefit from:

• Greater focus and agility within their respective fields
• Customized capital allocation strategies to pursue diversified growth objectives
• Increased strategic flexibility for mergers and acquisitions
• Distinct investment profiles to attract various investor bases
• Dedicated boards of directors and management teams aimed at maximizing value in their respective sectors

The Board of Directors has unanimously approved this plan after a comprehensive assessment of options following the recent acquisition of the fintech subsidiary.

Peter Tassiopoulos, CEO of ALT5 Sigma, commented, "This presents a remarkable opportunity to generate long-term, sustainable shareholder value through the establishment of two strong and unique companies. We believe this separation will unlock value for our shareholders and customers while creating new prospects for our employees. Importantly, each entity will have the independence to pursue its focused growth strategy, appropriate capital allocation, and portfolio-enhancing mergers and acquisitions."

ALT5 – Fintech Division

ALT5 will continue to concentrate on blockchain-enabled technologies facilitating the shift to a new global financial landscape. The company offers two primary platforms: "ALT5 Pay" and "ALT5 Prime." ALT5 Pay serves as a cryptocurrency payment gateway, allowing registered global merchants to manage cryptocurrency transactions or easily integrate the ALT5 Pay platform into their operations. ALT5 Prime is designed as an electronic over-the-counter trading platform for registered customers to trade digital assets, accessible through web applications, mobile apps, and the NYFIX gateway for authorized users.

Both ALT5 Pay and ALT5 Prime are seeing growing customer engagement, with transaction volumes surpassing $2 billion annually.

Alyea Therapeutics – Biotech Division

Alyea Therapeutics aims to establish itself as a leader in the development of non-addictive pain management therapies. The company plans to focus on addressing unmet medical needs and intends to strategize pathways to expedite the approval processes for its lead patented product, JAN123. This product, a Low Dose Naltrexone (LDN) with a biphasic release formulation, will pursue FDA approval through the 505(b)(2) pathway and has already received orphan drug designation. As part of its strategy, Alyea Therapeutics plans to initiate a large-scale multicenter clinical trial to support its New Drug Application (NDA) while exploring additional technologies to enhance its portfolio of non-opioid pain solutions.

In line with this restructuring, Dr. Amol Soin has been appointed as CEO of Alyea Therapeutics. Dr. Soin is established in the field of pain management, having founded The Ohio Pain Clinic and holding leadership positions in multiple medical societies. He has also been involved in the founding and development of several biotech firms achieving significant value in licensing and exit deals.

Tony Giordano has been named Chief Science Officer of Alyea Therapeutics. He brings extensive experience from multiple biotechnology companies and has a track record of leading successful drug development initiatives. Giordano has also been recognized for his collaborative work within innovation frameworks in healthcare.

The company plans to expand its management and board of directors for both entities, prioritizing the specific needs of each organization in the pursuit of their goals.